Liraglutide

CAS No. 204656-20-2

Liraglutide( Liraglutide | NNC 90-1170 | NN2211 | Saxenda, Victoza )

Catalog No. M18218 CAS No. 204656-20-2

Liraglutide is a long-acting GLP-1 receptor agonist.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 447 In Stock
10MG 527 In Stock
25MG 843 In Stock
50MG 1143 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Liraglutide
  • Note
    Research use only, not for human use.
  • Brief Description
    Liraglutide is a long-acting GLP-1 receptor agonist.
  • Description
    Liraglutide is an analog of Glucagon-like Peptide 1 (GLP-1) and an agonist of the Glucagon-like Peptide 1 receptor that is used as a hypoglycemic agent and supplemental therapy in the treatment of Diabetes by patients who do not respond to Metformin.(In Vitro):Liraglutide binds to the same receptors as does the endogenous metabolic hormone GLP-1. Liraglutide is an injectable drug for the treatment of type 2 diabetes, also can be used to treat obesity in adults with some related comorbidity. Liraglutide activated AMPK/SREBP1 pathway in oxLDL-stimulated Raw264.7 cells.
  • In Vitro
    Liraglutide binds to the same receptors as does the endogenous metabolic hormone GLP-1. Liraglutide is an injectable drugfor the treatment of type 2 diabetes, also can be used to treat obesity in adults with some related comorbidity. Liraglutide activated AMPK/SREBP1 pathway in oxLDL-stimulated Raw264.7 cells.
  • In Vivo
    ——
  • Synonyms
    Liraglutide | NNC 90-1170 | NN2211 | Saxenda, Victoza
  • Pathway
    Proteasome/Ubiquitin
  • Target
    Cysteine Protease
  • Recptor
    GLP-1
  • Research Area
    Endocrinology
  • Indication
    ——

Chemical Information

  • CAS Number
    204656-20-2
  • Formula Weight
    3751.25
  • Molecular Formula
    C172H265N43O51
  • Purity
    >98% (HPLC)
  • Solubility
    H2O : 5 mg/mL 1.33 mM
  • SMILES
    CCCCCCCCCCCCCCCC(=O)N[C@H](C(=O)O)CCC(=O)NCCCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)O)CCCNC(=N)N)CCCNC(=N)N)C(C)C)CC(C)C)Cc1c[nH]c2c1cccc2)C)[C@@H](CC)C)Cc1ccccc1)CCC(=O)O)NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]([C@@H](O)C)NC(=O)[C@@H](NC(=O)[C@H]([C@@H](O)C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](Cc1[nH]cnc1)N)C)CCC(=O)O)Cc1ccccc1)CO)CC(=O)O)CO)CO)Cc1ccc(cc1)O)CC(C)C)CCC(=O)O)CCC(=O)N)C)C
  • Chemical Name
    Glycine, L-histidyl-L-alanyl-L-alpha-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-alpha-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-N6-(N-(1-oxohexadecyl)-L-gamma-glutamyl)-L-lysyl-L-alpha-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Bode B, et al. Am J Manag Care. 2011 Mar;17(2 Suppl):S59-70.
molnova catalog
related products
  • MK-0674

    MK-0674 is an orally available, selective and potent cathepsin K inhibitor (IC50: 0.4 nM) that inhibits Cat B, Cat F, Cat L, and Cat S. It can be used in metabolism-related diseases.

  • PMSF

    PMSF (Phenylmethanesulfonyl fluoride) is an irreversible inhibitor of serine proteinases.

  • SID 26681509

    SID 26681509 is a selective, reversible and competitive human cathepsin L inhibitor (IC50 of 56 nM).